Cargando…

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation

The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs currently. In this review, the characteristics and interaction of bone metastases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chang, Wang, Miao, Xu, Changli, Li, Bo, Chen, Juxiang, Chen, Jianchun, Wang, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645368/ https://www.ncbi.nlm.nih.gov/pubmed/34877360 http://dx.doi.org/10.1155/2021/8970173

Ejemplares similares

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

The regulation of immune checkpoints by the hypoxic tumor microenvironment
por: Hu, Min, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2021)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
por: Chen, Xingyu, et al.
Publicado: (2021)

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases
por: Lehrer, Eric J., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Li, Xing, et al.
Publicado: (2020)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
por: Kim, Ryul, et al.
Publicado: (2019)

A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia
por: Aru, Başak, et al.
Publicado: (2023)

Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases
por: Moskalenko, Marina, et al.
Publicado: (2021)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
por: Wei, Yuxi, et al.
Publicado: (2023)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
por: Del Conte, Alessandro, et al.
Publicado: (2022)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Single isocenter stereotactic irradiation for multiple brain metastases: current situation and prospects
por: Uto, Megumi, et al.
Publicado: (2022)

Bone remodeling by checkpoint inhibitor
por: Kim, Hyeongjong, et al.
Publicado: (2020)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Seesaha, Poshita-Kumari, et al.
Publicado: (2021)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
por: Zhou, Qian, et al.
Publicado: (2021)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
por: Li, Xiaohua, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma
por: Yan, Zi-Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kocjfl9cqkbuuke24u8i7t6ijf